Stockscreener 앱 받기
6.12
2.17%
0.13
시간 외 거래:
6.20
0.08
+1.31%
Zura Bio Ltd 주식(ZURA)의 최신 뉴스
Zura Bio (NASDAQ: ZURA) outlines autoimmune pipeline, Phase 2 timelines - Stock Titan
Zura Bio GAAP EPS of -$1.06 misses by $0.31 - One News Page
Zura Bio 10-K: $0.0M Revenue, $(X.XX) EPS on reported net loss - TradingView
2025 financial update released as Zura Bio outlines new corporate developments - Traders Union
Zura Bio (NASDAQ: ZURA) raises cash to fund Phase 2 trials - Stock Titan
Zura says $144M financing can carry autoimmune drug trials into 2028 - Stock Titan
Ajay Nirula Net Worth (2026) - GuruFocus
Boothbay Fund Management LLC Acquires New Shares in Zura Bio Limited $ZURA - MarketBeat
Zura Bio Limited (NASDAQ:ZURA) Short Interest Up 16.2% in February - MarketBeat
Zura Bio Limited $ZURA Stock Holdings Boosted by Suvretta Capital Management LLC - MarketBeat
ZURA Technical Analysis & Stock Price Forecast - Intellectia AI
Atika Capital Management LLC Takes Position in Zura Bio Limited $ZURA - Defense World
Zura Bio’s Tibulizumab: First-in-Class Bispecific Antibody Targeting IL-17 and BAFF for Autoimmune Diseases (HS & SSc) – Pipeline, Trials, and Market Opportunity 2348 - Minichart
Zura Bio Updates Corporate Outlook on Lead Tibulizumab Program - TipRanks
Zura Bio updates corporate presentation, flags tibulizumab Phase 2 readouts, cash and shares - TradingView
Updated investor presentation furnished by Zura Bio (NASDAQ: ZURA) - Stock Titan
ZURA Stock Price, Quote & Chart | ZURA BIO LTD (NASDAQ:ZURA) - ChartMill
Zura Bio presents Phase 2 systemic sclerosis trial design By Investing.com - Investing.com Australia
Zura Bio presents Phase 2 systemic sclerosis trial design - Investing.com South Africa
Zura Bio launches Phase 2 TibuSURE trial in systemic sclerosis at Athens congress - Traders Union
Zura Bio to Present Phase 2 TibuSURE Study Design Poster Evaluating Dual IL-17A and BAFF Inhibition in Systemic Sclerosis at 9th Systemic Sclerosis World Congress - Weekly Voice
Director at Zura Bio (ZURA) awarded 37,812 share options - Stock Titan
Major Zura Bio (ZURA) holder acquires 2M shares in registered deal - Stock Titan
Access Industries group lifts Zura Bio (ZURA) stake to 18.2% - Stock Titan
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
Zura Bio heads to Miami for March 10-11 investor conferences - Stock Titan
Zura Bio raises $144 million in public offering of shares By Investing.com - Investing.com South Africa
Zura Bio raises $144 million in public offering of shares - Investing.com India
Zura Bio Announces Closing of its $144 Million Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares - ChartMill
Zura Bio (ZURA) revises Ogier legal opinion and consent in 8-K/A - Stock Titan
Zura Bio prices $125M public offering at $6.25 per share - Investing.com Australia
Zura Bio (ZURA) launches $6.25 share and pre-funded warrant sale - Stock Titan
Zura Bio (NASDAQ: ZURA) seeks roughly $117M from 18.2M-share offering - Stock Titan
Zura Bio Prices Public Offering of 18.2 Million Shares - Intellectia AI
Zura Bio prices $125M public offering at $6.25 per share By Investing.com - Investing.com South Africa
Zura Bio launches public offering of Class A shares By Investing.com - Investing.com India
Zura Bio Announces Pricing of $125 Million Public Offering of Class A Ordinary Shares and Pre-Funded Warrants - ChartMill
Zura Bio launches public offering of Class A shares - Investing.com Australia
Director Mark Eisner files initial Form 3 for Zura Bio Ltd (ZURA) - Stock Titan
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
Zura Bio Announces Proposed Public Offering of Class A Ordinary Shares and Pre-Funded Warrants - Stock Titan
Zura Bio adds two immunology executives to board By Investing.com - Investing.com India
Zura Bio adds two immunology executives to board - Investing.com
Zura Bio (ZURA) appoints Mark Eisner and Ajay Nirula to its board - Stock Titan
Zura Bio Welcomes Accomplished Drug Development Leaders Mark Eisner, M.D., M.P.H., and Ajay Nirula, M.D., Ph.D., to Board of Directors - ChartMill
Risk Recap: What makes Zura Bio Limited stock attractive todayMarket Sentiment Report & Community Consensus Picks - baoquankhu1.vn
What risks investors should watch in Zura Bio Limited stockGDP Growth & Weekly High Momentum Picks - mfd.ru
Great Point discloses 3.8M Zura Bio (ZURA) shares in 13G/A - Stock Titan
Zura Bio Highlights Key Phase 2 Tibulizumab Readouts at Guggenheim Biotech Summit 2026 - Yahoo Finance
Zura Bio Limited (NASDAQ:ZURA) Short Interest Up 27.7% in January - MarketBeat
Why retail investors favor Zura Bio Limited stockWeekly Stock Recap & Daily Momentum Trading Reports - mfd.ru
ZURA PE Ratio & Valuation, Is ZURA Overvalued - Intellectia AI
Zura Bio Advances Tibulizumab Strategy in Autoimmune Diseases - TipRanks
Zura Bio Ltd Provides Updated Corporate Presentation - TradingView
This Nokia Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
Wedbush initiates coverage on Zura Bio stock with Outperform rating By Investing.com - Investing.com India
Wedbush initiates coverage on Zura Bio stock with Outperform rating - Investing.com
Wedbush Initiates Zura Bio at Outperform With $15 Price Target - marketscreener.com
Investment Report: Will Zura Bio Limited benefit from rising consumer demand2025 Short Interest & AI Driven Price Predictions - baoquankhu1.vn
Aug Update: Will Zura Bio Limited benefit from rising consumer demandJuly 2025 Chart Watch & Safe Capital Allocation Plans - baoquankhu1.vn
Zura Bio to Participate in the Guggenheim Emerging Outlook: Biotech Summit - ChartMill
Watch Zura Bio's Guggenheim biotech summit fireside chat live online - Stock Titan
Aug Sectors: What makes Zura Bio Limited stock attractive todayTrade Risk Assessment & Capital Protection Trading Alerts - baoquankhu1.vn
Zura Bio Limited (NASDAQ:ZURA) Given Average Rating of “Moderate Buy” by Brokerages - Defense World
Pre-market volume spike for 94E.F Zura Bio (XETRA) 28 Jan 2026: watch EUR 5.20 level - Meyka
1.20%
0.06%
자본화:
|
볼륨(24시간):